ArticleJournal of clinical medicine2022
Adenoid Cystic Carcinoma of the Breast May Be Exempt from Adjuvant Chemotherapy.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Adenoid cystic carcinoma of the breast: report of the diagnosis and management of two cases.International journal of surgery case reports · 2026Article
- Ultrasound features and clinicopathologic correlations of breast adenoid cystic carcinoma: a retrospective observational study.Translational cancer research · 2026Article
- Adenoid cystic carcinoma of the breast: a case series of 26 patients.Breast cancer research and treatment · 2026Article
- Adenoid Cystic Carcinoma of the Male Breast: An Exceptionally Rare Presentation.Case reports in pathology · 2026Article
- The effect of adjuvant radiotherapy on M0 adenoid cystic carcinoma of the breast: a retrospective cohort study based on SEER data.Gland surgery · 2025Article
- Adenoid cystic carcinoma of the breast with aggressive behavior: A case report and review of the literature.Oncology letters · 2025Article
- Rare hepatic metastasis in classical adenoid cystic carcinoma of the breast: A case report.Oncology letters · 2025Article
- Analysis of clinicopathological features and clinical significance in 25 cases of mammary adenoid cystic carcinoma.BMC women's health · 2025Article
- Review
- Solid subtype of adenoid cystic carcinoma of the breast with multiple distant metastases: a case report and literature review.Frontiers in oncology · 2025Article
- Real-world insights on a rare disease: adenoid cystic carcinoma of the breast.Ecancermedicalscience · 2025Article
- Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations.Current breast cancer reports · 2024Article
- Locally Advanced Adenoid Cystic Carcinoma of the Breast-A Case Report with a Review of the Literature.Medicina (Kaunas, Lithuania) · 2023Review
- Optimal surgical procedure for treating early-stage adenoid cystic carcinoma of the breast.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Consistent standards regarding whether postoperative adjuvant chemotherapy is required in the treatment of adenoid cystic carcinoma of the breast (ACCB) are currently lacking. Using clinical data from the Surveillance, Epidemiology, and End Results (SEER) database (1988−2015), and the National Cancer Center of China (2004−2020), we retrospectively analyzed patients with ACCB who received radical treatment. A total of 661 patients were eligible. The median age at diagnosis was 61 years; 99.5% of patients were initially diagnosed with stage I and II breast cancer, and 76.7% had triple-negative breast cancer. Only 12.4% of patients received adjuvant chemotherapy. Multivariate analysis showed that patients with lymph node metastasis and non-radiotherapy had worse overall survival (OS) (p < 0.05). Patients with lymph node metastasis, stage IIB and III, histological grade ≥ 2, and non-radiotherapy had worse breast cancer-specific survival (BCSS) (p < 0.05). Adjuvant chemotherapy did not improve the OS or BCSS. Patients treated with adjuvant chemotherapy also had no better survival outcomes after propensity score matching. External data verification confirmed that chemotherapy did not improve disease-free survival or OS. Adjuvant chemotherapy cannot improve the clinical outcomes of ACCB, even in subgroups with a high risk of recurrence and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.